此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects

2020年12月6日 更新者:Novartis Pharmaceuticals

An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Mild, Moderate or Severe Renal Impairment Compared to Age, Sex, and Body Weight-matched Healthy Subjects

The aim of this study was to characterize the pharmacokinetics and safety of AFQ056 in subjects with a different degree of renal impairment.

研究概览

地位

完全的

干预/治疗

研究类型

介入性

注册 (实际的)

48

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Kiel、德国
        • Novartis Investigative Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Written informed consent must be obtained before any assessment is performed.
  • Female subjects must be of non-child bearing potential as defined as postmenopausal females with no regular menstrual bleeding for at least 1 year prior to inclusion
  • Body weight: ≥50kg; BMI: 18-34 kg/m2
  • Ability to communicate well with the investigator and comply with the requirements of the study.

For subjects with renal impairment only

  • No current clinically significant disease (other than renal impairment), except for stable underlying disease that caused renal impairment, as determined by clinical history and physical examination.
  • MDRD-calculated eGFR of <90 mL/min/1.73 m2 based on serum creatinine
  • Vital signs (after 3 minutes resting measured in the supine position) should be within normal ranges as deemed by the Investigator.

For healthy subjects only

  • No current clinically significant disease as determined by clinical history and physical examination.
  • MDRD-calculated eGFR of ≥90 mL/min/1.73 m2 based on serum creatinine.
  • Vital signs (after 3 minutes resting measured in the supine position) should be within normal ranges as deemed by the Investigator.

Exclusion Criteria:

  • Pregnant or nursing (lactating) females
  • Use of any prescription or over-the-counter (OTC) drugs, herbal (e.g. St. John's wort) ordietary supplements (e.g. broccoli, vitamins) within three weeks or five half lives(whichever is longer) prior to dosing with AFQ056 until study completion. This does not include drugs that are used as (symptomatic) treatment of renal impairment (e.g. antihypertensive and antidiabetic drugs) provided such drugs are:

    • used at the same dose within three weeks or five half lives (whichever is longer) prior to dosing with AFQ056 until study completion.
    • not known as inhibitors or inducers of CYP1A1, 1A2, 2C8, 2C9, 2C19, 3A4, 3A5 gp).
  • Participation in any clinical investigation or use of any investigational drug within 30 days or five (5) half-lives of a given investigational drug (whichever period is longer); or longer if required by local regulations prior to screening until study completion
  • Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
  • History of renal transplantation
  • History or presence of prolonged QTc interval (males: >450ms; females: > 470 ms), 2nd or 3rd degree AV-block or any other clinically significant ECG abnormalities as determined by medical history and 12-lead ECG recordings at screening and baseline 1.
  • History or presence of any clinically significant disease of any major system organ class, within the past 2 years prior to screening, except for renal impairment and underlying diseases causing renal impairment for the subject belonging to the renal impairment groups.
  • Subjects undergoing any method of dialysis (hemodialysis or peritoneal dialysis)
  • History of or ongoing active substance abuse (including alcohol) within the past 2 years.
  • Smokers (use of tobacco products in the previous 3 months). Urine cotinine levels will be measured during Screening and at Baseline for all subjects. Smokers will be defined as any subject who reports tobacco use and/or who has a urine cotinine ≥ 500 ng/mL at screening

Other protocol-defined inclusion/exclusion criteria may apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:不适用
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:All study subjects

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Measure: Area under the plasma concentration-time curve from time zero to infinity (AUCinf)
大体时间:0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
Measure: Area under the curve from time zero to the last measurable concentration sampling time (Tlast) [mass x time x volume-1] (AUClast)
大体时间:0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
Measure: Maximum observed plasma concentration (Cmax)
大体时间:0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
Measure: Time to Reach Maximum Observed Plasma Concentration (Tmax)
大体时间:0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
Measure: Terminal elimination half-life (T1/2)
大体时间:0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
Measure: The apparent systemic (or total body) clearance from plasma following extravascular administration [volume / time] (CL/F)
大体时间:0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
Measure: The apparent volume of distribution during the terminal elimination phase following oral administration [volume] (Vz/F)
大体时间:0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
Measure: Amount of drug excreted into the urine from time zero to time't' where t is a defined time point after administration [mass units or % of dose] (Ae0-t)
大体时间:4 days
4 days
Measure: The renal clearance from plasma [volume / time] (CLr)
大体时间:4 days
4 days

次要结果测量

结果测量
大体时间
Physical examination
大体时间:Screening, Day -1, Day 8 +/- 2 days
Screening, Day -1, Day 8 +/- 2 days
Measure: Vital signs and body measurements
大体时间:Screening, Day -1, Day 1, Day 8 +/- 2 days
Screening, Day -1, Day 1, Day 8 +/- 2 days
Measure: ECG
大体时间:Screening, Day -1, Day 1, Day 8 +/- 2 days
Screening, Day -1, Day 1, Day 8 +/- 2 days
Measure: pulse oximetry
大体时间:Screening, Day -1, Day 1, Day 8 +/- 2 days
Screening, Day -1, Day 1, Day 8 +/- 2 days
Measure: hematology
大体时间:Screening, Day -1, Day 4, Day 8 +/- 2 days
Screening, Day -1, Day 4, Day 8 +/- 2 days
Measure: blood chemistry
大体时间:Screening, Day -1, Day 2, Day 4, Day 8 +/- 2 days
Screening, Day -1, Day 2, Day 4, Day 8 +/- 2 days
Measure: urinalysis
大体时间:Screening, Day -1, Day 4, Day 8 +/- 2 days
Screening, Day -1, Day 4, Day 8 +/- 2 days
Measure: AE (adverse events) monitoring
大体时间:During the study (up to 10 days)
During the study (up to 10 days)
SAE (serious adverse events) monitoring
大体时间:During the study (up to 10 days) and up to 30 days after study completion
During the study (up to 10 days) and up to 30 days after study completion

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2011年1月1日

初级完成 (实际的)

2011年8月1日

研究完成 (实际的)

2011年8月1日

研究注册日期

首次提交

2011年9月9日

首先提交符合 QC 标准的

2011年9月27日

首次发布 (估计)

2011年9月28日

研究记录更新

最后更新发布 (实际的)

2020年12月8日

上次提交的符合 QC 标准的更新

2020年12月6日

最后验证

2017年2月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • CAFQ056A2124
  • 2010-022738-94 (EudraCT编号)

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅